Literature DB >> 1432124

Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage.

Y Kaku1, Y Yonekawa, T Tsukahara, K Kazekawa.   

Abstract

This report describes the successful treatment of cerebral vasospasm after subarachnoid hemorrhage with superselective intra-arterial infusion of papaverine hydrochloride. Thirty-seven vascular territories in 10 patients with symptomatic vasospasm were treated according to the following protocol. Percutaneous transluminal angioplasty was performed in two steps. First, a silicone balloon was used for dilation of the internal carotid artery and the proximal portions of the middle cerebral artery. A silicone leak balloon or Tracker-18 catheter was then introduced into or just proximal to the site of vasospasm not accessible to the angioplasty balloon catheter for superselective infusion of 0.2% papaverine. Thirty-four of 37 vascular territories were successfully dilated, and eight of 10 patients showed improvement in neurological function after the procedure. There were no serious side effects due to infusion of papaverine. It is essential to infuse the papaverine just proximal to the spastic vessels in order to deliver sufficient concentration of drug, and infusion should be carried out as early as possible before the artery loses its ability to return to a normal luminal size. Superselective intraarterial infusion of papaverine is an alternative method of treatment for symptomatic vasospasm.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1432124     DOI: 10.3171/jns.1992.77.6.0842

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  37 in total

1.  Mechanical and pharmacologic treatment of vasospasm.

Authors: 
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

2.  Intra-arterial papaverine used to treat cerebral vasospasm reduces brain oxygen.

Authors:  Michael F Stiefel; Alejandro M Spiotta; Joshua D Udoetuk; Eileen Maloney-Wilensky; John B Weigele; Robert W Hurst; Peter D LeRoux
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

3.  Endovascular management of cerebral aneurysms.

Authors:  A Berenstein
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

Review 4.  Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage.

Authors:  James K Liu; William T Couldwell
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain.

Authors:  Mansi Krishan; Gary A Gudelsky; Pankaj B Desai; Mary Beth Genter
Journal:  Drug Deliv       Date:  2013-10-14       Impact factor: 6.419

6.  Effects of prophylactic intrathecal administrations of nicardipine on vasospasm in patients with severe aneurysmal subarachnoid haemorrhage.

Authors:  M Shibuya; Y Suzuki; H Enomoto; T Okada; K Ogura; K Sugita
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

7.  Combined endovascular treatment for both intracranial aneurysm and symptomatic vasospasm.

Authors:  Yuichi Murayama; Joon K Song; Ken Uda; Y Pierre Gobin; Gary R Duckwiler; Satoshi Tateshima; Aman B Patel; Neil A Martin; Fernando Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

8.  Intra-arterial colforsin daropate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  Satoshi Suzuki; Osamu Ito; Tetsuro Sayama; Katsuya Goto
Journal:  Neuroradiology       Date:  2009-12-02       Impact factor: 2.804

9.  Quadruple H therapy for vasospasm.

Authors:  M Sami Walid; Nadezhda V Zaytseva
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

10.  Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm.

Authors:  Neeraj Badjatia; Mehmet A Topcuoglu; Johnny C Pryor; James D Rabinov; Christopher S Ogilvy; Bob S Carter; Guy A Rordorf
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.